Cidara buys back rights to flu therapy from J&J for $85m
Cidara Therapeutics has entered into a definitive agreement with Johnson & Johnson (J&) to buy back the rights to its…
Cidara Therapeutics has entered into a definitive agreement with Johnson & Johnson (J&) to buy back the rights to its…
Mundipharma has signed an agreement to acquire all assets and rights related to antifungal candidate Rezzayo (rezafungin) from Cidara Therapeutics, including ongoing development and distribution. The assets and rights will…
Incyte has agreed to acquire US-based Escient Pharmaceuticals and its assets, including two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast…
Century Therapeutics has acquired US-based Clade Therapeutics, which specialises in allogeneic cell therapies, to expand its pipeline of cancer and autoimmune therapies. For the acquisition, Century will pay an upfront…
US-based Eliem Therapeutics has announced a definitive agreement for the acquisition of development-stage private biotechnology company Tenet Medicines. The acquisition is aimed at enhancing Eliem’s portfolio with a clinical-stage programme…
Kintara Therapeutics has signed a definitive agreement to execute an all-stock merger with TuHURA Biosciences to form a company for developing late-stage oncology assets. The merged entity, set to operate…
Aditxt has announced a definitive agreement under which its subsidiary, Adivir, will acquire complete issued and outstanding Class A common shares of biopharmaceutical company Appili Therapeutics. The move enhances Aditxt's…